First-in-human phase I and pharmacological study of TAS-119, a selective Aurora A (AurA) kinase inhibitor, in patients (pts) with advanced solid tumors.

Debbie Robbrecht,Ferry A.L.M. Eskens,Emiliano Calvo,Xiaomin He,Hiroshi Hirai,Nital Soni,Natalie Cook,Afshin Dowlati,Angelica Fasolo,Victor Moreno,Johann S. de Bono

First-in-human phase I and pharmacological study of TAS-119, a selective Aurora A (AurA) kinase inhibitor, in patients (pts) with advanced solid tumors.

2019

Debbie Robbrecht
Ferry A.L.M. Eskens
Emiliano Calvo
Xiaomin He
Hiroshi Hirai
Nital Soni
Natalie Cook
Afshin Dowlati
Angelica Fasolo
Victor Moreno
Johann S. de Bono

3063Background: AurA is a serine threonine kinase regulating cell division and cell cycle progression and has a role in carcinogenesis. This clinical trial investigated safety, pharmacokinetics and...

Keywords:

Cancer research
Aura
Pathology
Kinase
Medicine
Serine/threonine-specific protein kinase
Carcinogenesis
in patient
Cell division
Clinical trial
Pharmacokinetics

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations